SillaJen's BAL0891 confirms anticancer effect at European Society for Medical Oncology; response rate of 21.4% in combination group
Predicted impact: Low
Conference data on BAL0891 repeats trial results already reported in the last 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.